Provided By GlobeNewswire
Last update: May 6, 2025
WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2025 and provided general business updates.
Read more at globenewswire.comNASDAQ:GNLX (8/21/2025, 11:25:35 AM)
3.42
+0.06 (+1.79%)
Find more stocks in the Stock Screener